Adeno-Associated Virus (AAV) Gene Therapy Market
Adeno-Associated Virus (AAV) Gene Therapy Market - Global Industry Assessment & Forecast
#
Pages:
252
2023
Nov - 2024
VMR-3163
Segments Covered
By
Types Luxturna, Zolgensma, Others
-
By
Applications Central Nervous System Diseases, Ocular Diseases, Liver-directed Diseases, Other Hereditary Diseases
Snapshot
 Base Year:
|
2023 |
| Forecast
Years:
|
2024 - 2032 |
 Historical
Years:
|
2018 - 2022 |
 Revenue
2023: |
USD XX Million |
 Revenue 2032:
|
USD XX Million |
 Revenue CAGR
(2024 - 2032): |
XX |
Fastest Growing Region (2024 -
2032)
|
XX |
Largest Region (2023):
|
XX |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
| Sr. No. | Offering | Report Coverage |
| 1. | Market Size | In terms of Revenue (USD Million) |
| 2. | Historic Data | 2018 to 2022 |
| 3. | Forecast Data | 2024 to 2032 |
| 4. | Market Drivers, Restraints, Opportunities, & Regional Market Trends | Yes |
| 5. | Market Attractiveness Analysis | Yes |
| 6. | Segment Analysis | Maximum Segments |
| 7. | Regional Coverage | 5 Regions |
| 8. | Country Coverage | Top 22 Countries |
| 9. | Competitive Landscape and Company Market Share Analysis | Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles. |
| 10. | Porter’s Five Forces Analysis | Yes. |
| 11. | Value Chain Analysis | Yes |
| 12. | PEST Analysis | Yes |
| 13. | Regulatory Landscape | Yes |
| 14. | Technology Landscape | Yes |
| 15. | COVID-19 Impact Analysis | Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics. |
| 16. | Top startups to watch out for | Yes |
| 17. | Top 3 Trends to Watch | Yes |
| 18. | Top 3 Strategies Followed by Major Players | Yes |
| 19. | Top 3 Predictions by Vantage Market Research | Yes |
| 20. | Discussion Guide | Yes |
| 21. | Key Primary Respondents - VERBATIM | Yes |
| 22. | Transcripts from the Primary Respondents | Additional Cost USD 1,000 |
| 23. | Others/Miscellaneous | |
FAQ
Frequently Asked Question
What is the global demand for Adeno-Associated Virus (AAV) Gene Therapy in terms of revenue?
-
The global Adeno-Associated Virus (AAV) Gene Therapy valued at USD XX Million in 2023 and is expected to reach USD XX Million in 2032 growing at a CAGR of XX.
Which are the prominent players in the market?
-
The prominent players in the market are Creative Biolabs,Affinia Therapeutics,Spark Therapeutics,AGC Biologics,StrideBio,SIRION Biotech,Neurophth Biotechnology,Belief BioMed,BiBo Biopharma Engineering Co., LTD.,Beihai Kangcheng,PackGene Biotech,Sarepta Therapeutics,Carbon BioSciences,Kelonia Therapeutics,Roche,Remedium Bio.
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of XX between 2024 and 2032.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Adeno-Associated Virus (AAV) Gene Therapy include
Which region accounted for the largest share in the market?
-
XX was the leading regional segment of the Adeno-Associated Virus (AAV) Gene Therapy in 2023.
